Advertisement
Research Article|Articles in Press, 110633

Low-density lipoprotein cholesterol levels are associated with first-phase insulin release

Published:March 18, 2023DOI:https://doi.org/10.1016/j.diabres.2023.110633
Low-density lipoprotein cholesterol levels are associated with first-phase insulin release
Previous ArticleAssociation between neutrophil/lymphocyte ratio and kidney impairment in type 2 diabetes mellitus: a role of extracellular water/total body water ratio
Next ArticleSwitching to an advanced hybrid closed-loop system in real-world practice improves hypoglycemia awareness and metabolic control in adults with type 1 diabetes, particularly in those with impaired perception of hypoglycemia symptoms

      Abstract

      Aims

      Prior studies provided evidence that low-density lipoprotein (LDL)-cholesterol-lowering statins reduce cardiovascular events while conveying an increased risk of type 2 diabetes. The aim of this study was to investigate the association between LDL levels and both insulin sensitivity and insulin secretion in a cohort of 356 adult first-degree relatives of patients with type 2 diabetes.

      Methods

      Insulin sensitivity was assessed by euglycemic hyperinsulinemic clamp and first-phase insulin secretion was measured by both intravenous glucose tolerance test (IVGTT) and OGTT.

      Results

      LDL-cholesterol levels were not independently associated with insulin-stimulated glucose disposal. After adjusting for several potential confounders, LDL-cholesterol concentration exhibited a positive independent association with acute insulin response (AIR) during IVGTT and with the OGTT derived Stumvoll first-phase insulin secretion index. When insulin release was adjusted for the underlying degree of insulin sensitivity, using the disposition index (AIR x insulin-stimulated glucose disposal), β-cell function was significantly associated with LDL-cholesterol levels, even after further adjusting for several potential confounders.

      Conclusions

      The present results suggest that LDL cholesterol is a positive modulator of insulin secretion. The deterioration in glycemic control observed during treatment with statins might thus be explained by an impairment in insulin secretion due to the cholesterol-lowering effect of statins.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Diabetes Research and Clinical Practice
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Perego C.
        • Da Dalt L.
        • Pirillo A.
        • Galli A.
        • Catapano A.L.
        • Norata G.D.
        Cholesterol metabolism, pancreatic β-cell function and diabetes.
        Biochim Biophys Acta Mol Basis Dis. 2019; 1865: 2149-2156
        View in Article

      2. Cholesterol Treatment Trialists (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371:117–25.

        View in Article

      3. Cholesterol Treatment Trialists (CTT) Collaborators, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376:1670–81.

        View in Article
        • Carter A.A.
        • Gomes T.
        • Camacho X.
        • Juurlink D.N.
        • Shah B.R.
        • Mamdani M.M.
        Risk of incident diabetes among patients treated with statins: population based study.
        BMJ. 2013; 346f2610
        View in Article
        • Wang K.L.
        • Liu C.J.
        • Chao T.F.
        • Huang C.M.
        • Wu C.H.
        • Chen S.J.
        • et al.
        Statins, risk of diabetes, and implications on outcomes in the general population.
        J Am Coll Cardiol. 2012; 60: 1231-2128
        View in Article
        • Boekholdt S.M.
        • Arsenault B.J.
        • Mora S.
        • Pedersen T.R.
        • LaRosa J.C.
        • Nestel P.J.
        • et al.
        Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.
        JAMA. 2012; 307: 1302-1309
        View in Article
        • Sattar N.
        • Preiss D.
        • Murray H.M.
        • Welsh P.
        • Buckley B.M.
        • de Craen A.J.M.
        • et al.
        Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.
        Lancet. 2010; 375: 735-742
        View in Article
        • Preiss D.
        • Seshasai S.R.
        • Welsh P.
        • Murphy S.A.
        • Ho J.E.
        • Waters D.D.
        • et al.
        Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.
        JAMA. 2011; 305: 2556-2564
        View in Article
        • Feng Q.
        • Wei W.Q.
        • Chung C.P.
        • Levinson R.T.
        • Sundermann A.C.
        • Mosley J.D.
        • et al.
        Relationship between very low low-density lipoprotein cholesterol concentrations not due to statin therapy and risk of type 2 diabetes: a US-based cross-sectional observational study using electronic health records.
        PLoS Med. 2018; 15: e1002642
        View in Article
        • Andersson C.
        • Lyass A.
        • Larson M.G.
        • Robins S.J.
        • Vasan R.S.
        Low-density lipoprotein cholesterol concentrations and risk of incident diabetes: epidemiological and genetic insights from the Framingham Heart Study.
        Diabetologia. 2015; 58: 2774-2780
        View in Article
        • Casula M.
        • Mozzanica F.
        • Scotti L.
        • Tragni E.
        • Pirillo A.
        • Corrao G.
        • et al.
        Statin use and risk of new-onset diabetes: a meta-analysis of observational studies.
        Nutr Metab Cardiovasc Dis. 2017; 27: 396-406
        View in Article
        • Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JE, Shah T, Sofat R, Stender S, Johnson PC, Scott RA, Leusink M, Verweij N, Sharp SJ, Guo Y, Giambartolomei C, Chung C, Peasey A, Amuzu A, Li K, Palmen J, Howard P, Cooper JA, Drenos F, Li YR, Lowe G, Gallacher J, Stewart MC, Tzoulaki I, Buxbaum SG, van der A DL, Forouhi NG, Onland-Moret NC, van der Schouw YT, Schnabel RB, Hubacek JA, Kubinova R, Baceviciene M, Tamosiunas A, Pajak A, Topor-Madry R, Stepaniak U, Malyutina S, Baldassarre D, Sennblad B, Tremoli E, de Faire U, Veglia F, Ford I, Jukema JW, Westendorp RG, de Borst GJ, de Jong PA, Algra A, Spiering W, Maitland-van der Zee AH, Klungel OH, de Boer A, Doevendans PA, Eaton CB, Robinson JG, Duggan D; DIAGRAM Consortium; MAGIC Consortium; InterAct Consortium; Kjekshus J, Downs JR, Gotto AM, Keech AC, Marchioli R, Tognoni G, Sever PS, Poulter NR, Waters DD, Pedersen TR, Amarenco P, Nakamura H, McMurray JJ, Lewsey JD, Chasman DI, Ridker PM, Maggioni AP, Tavazzi L, Ray KK, Seshasai SR, Manson JE, Price JF, Whincup PH, Morris RW, Lawlor DA, Smith GD, Ben-Shlomo Y, Schreiner PJ, Fornage M, Siscovick DS, Cushman M, Kumari M, Wareham NJ, Verschuren WM, Redline S, Patel SR, Whittaker JC, Hamsten A, Delaney JA, Dale C, Gaunt TR, Wong A, Kuh D, Hardy R, Kathiresan S, Castillo BA, van der Harst P, Brunner EJ, Tybjaerg-Hansen A, Marmot MG, Krauss RM, Tsai M, Coresh J, Hoogeveen RC, Psaty BM, Lange LA, Hakonarson H, Dudbridge F, Humphries SE, Talmud PJ, Kivimäki M, Timpson NJ, Langenberg C, Asselbergs FW, Voevoda M, Bobak M, Pikhart H, Wilson JG, Reiner AP, Keating BJ, Hingorani AD, Sattar N
        HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials.
        Lancet. 2015; 385: 351-361
        View in Article
        • Ference B.A.
        • Robinson J.G.
        • Brook R.D.
        • Catapano A.L.
        • Chapman M.J.
        • Neff D.R.
        • et al.
        Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes.
        N Engl J Med. 2016; 375: 2144-2153
        View in Article
        • Lotta L.A.
        • Sharp S.J.
        • Burgess S.
        • Perry J.R.B.
        • Stewart I.D.
        • Willems S.M.
        • et al.
        Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis.
        JAMA. 2016; 316: 1383-1391
        View in Article
        • Klimentidis Y.C.
        • Arora A.
        • Newell M.
        • Zhou J.
        • Ordovas J.M.
        • Renquist B.J.
        • et al.
        Phenotypic and genetic characterization of lower LDL cholesterol and increased type 2 diabetes risk in the UK Biobank.
        Diabetes. 2020; 69: 2194-2205
        View in Article

      16. Rui Fu 1, Kongyong Cui 1, Jingang Yang 2, et al.; CAMI Registry Investigators; Fasting stress hyperglycemia ratio and in-hospital mortality after acute myocardial infarction in patients with different glucose metabolism status: Results from China acute myocardial infarction registry. Diabetes Res Clin Pract 2023 Feb; 196:110241.

        View in Article

      17. Pasquale Mone, Angela Lombardi, Luigi Salemme, Angelo Cioppa, Grigore Popusoi, Fahimeh Varzideh, Antonella Pansini, Stanislovas S. Jankauskas, Imma Forzano, Roberta Avvisato, Xujun Wang, Tullio Tesorio, Gaetano Santulli; Stress Hyperglycemia Drives the Risk of Hospitalization for Chest Pain in Patients With Ischemia and Nonobstructive Coronary Arteries (INOCA). Diabetes Care 1 February 2023; 46 (2): 450–454.

        View in Article
        • Natali A.
        • Baldi S.
        • Bonnet F.
        • Petrie J.
        • Trifirò S.
        • Tricò D.
        • et al.
        Plasma HDL-cholesterol and triglycerides, but not LDL-cholesterol, are associated with insulin secretion in non-diabetic subjects.
        Metabolism. 2017; 69: 33-42
        View in Article
        • Dannecker C.
        • Wagner R.
        • Peter A.
        • Hummel J.
        • Vosseler A.
        • Häring H.U.
        • et al.
        Low-Density lipoprotein cholesterol is associated with insulin secretion.
        J Clin Endocrinol Metab. 2021; 106: 1576-1584
        View in Article
        • Mone P.
        • Varzideh F.
        • Kansakar U.
        • Infante C.
        • Lombardi A.
        • de Donato A.
        • et al.
        Omega-3 fatty acids coordinate glucose and lipid metabolism in diabetic patients.
        Lipids Health Dis. 2022 Mar 25; 21: 31
        View in Article
        • Laakso M.
        • Zilinskaite J.
        • Hansen T.
        • Boesgaard T.W.
        • Vänttinen M.
        • Stancáková A.
        • et al.
        EUGENE2 Consortium. Insulin sensitivity, insulin release and GLP-1 levels in subjects with IFG and/or IGT in the EUGENE2 study.
        Diabetologia. 2008; 51: 502-511
        View in Article
        • Succurro E.
        • Marini M.A.
        • Riccio A.
        • Fiorentino T.V.
        • Perticone M.
        • Sciacqua A.
        • et al.
        Sex-differences in insulin sensitivity and insulin secretion in subjects with impaired fasting glucose and impaired glucose tolerance.
        Diabetes Res Clin Pract. 2022; 194110185
        View in Article
        • Succurro E.
        • Frontoni S.
        • Mastroianni S.
        • Arturi F.
        • Sciacqua A.
        • Lauro R.
        • et al.
        Insulin sensitivity, β-cell function, and incretin effect in individuals with elevated 1-h postload plasma glucose levels.
        Diabetes Care. 2012; 35: 868-872
        View in Article
        • Marini M.A.
        • Frontoni S.
        • Succurro E.
        • Arturi F.
        • Sciacqua A.
        • Hribal M.L.
        • et al.
        Insulin sensitivity, and β-cell function in relation to hemoglobin A1C.
        Nutr Metab Cardiovasc Dis. 2014; 24: 27-33
        View in Article
        • Hanson R.L.
        • Pratley R.E.
        • Bogardus C.
        • Narayan K.M.
        • Roumain J.M.
        • Imperatore G.
        • et al.
        Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies.
        Am J Epidemiol. 2000; 151: 190-198
        View in Article
        • Stumvoll M.
        • Mitrakou A.
        • Pimenta W.
        • Jenssen T.
        • Yki-Jarvinen H.
        • Van Haeften T.
        • et al.
        Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity.
        Diabetes Care. 2000; 23: 295-301
        View in Article

      27. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes—2023. Diabetes Care 2023;46(Suppl. 1:S19–S40.

        View in Article
        • Stancáková A.
        • Javorský M.
        • Kuulasmaa T.
        • Haffner S.M.
        • Kuusisto J.
        • Laakso M.
        Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men.
        Diabetes. 2009; 58: 1212-1221
        View in Article

      29. Tara M. Wallace, Jonathan C. Levy, David R. Matthews; Use and Abuse of HOMA Modeling. Diabetes Care 1 June 2004; 27 (6): 1487–1495.

        View in Article
        • Balducci S.
        • Haxhi J.
        • Vitale M.
        • Mattia L.
        • Bollanti L.
        • Conti F.
        • et al.
        Italian Diabetes, Exercise Study 2 IDES_2 Investigators. Sustained decreases in sedentary time and increases in physical activity are associated with preservation of estimated β-cell function in individuals with type 2 diabetes.
        Diabetes Res Clin Pract. 2022 Nov; 193
        View in Article
        • Nauck M.A.
        • Meier J.J.
        The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions.
        Lancet Diabetes Endocrinol. 2016; 4: 525-536
        View in Article
        • Holst J.J.
        The incretin system in healthy humans: The role of GIP and GLP-1.
        Metabolism. 2019; 96: 46-55
        View in Article

      Article info

      Publication history

      Accepted: March 15, 2023
      Received in revised form: March 13, 2023
      Received: January 21, 2023

      Publication stage

      In Press Journal Pre-Proof

      Identification

      DOI: https://doi.org/10.1016/j.diabres.2023.110633

      Copyright

      © 2023 Elsevier B.V. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX